## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.40 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($213.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025**
- Source: ts2.tech | 20251214T213642 | Bullish | Relevance: 100%
- AbbVie (NYSE: ABBV) heads into December 15, 2025, with strong performance, bolstered by analyst upgrades from HSBC and Morgan Stanley, and robust growth in Skyrizi and Rinvoq which are offsetting Humira erosion. The company also announced a 5.5% dividend increase, and positive pipeline developments in neuroscience and oncology are building further long-term optionality. Despite these positives, investors are monitoring risks such as policy uncertainty, aesthetics business sensitivity, and ongoing legal disputes.

**2. AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025â€”and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251213T032045 | Neutral | Relevance: 100%
- AbbVie Inc. (NYSE: ABBV) experienced a modest decline on December 12, 2025, both during regular trading hours and in after-hours, mirroring a broader market retreat. Key movements included a raised price target from Morgan Stanley to $269, alongside a cautionary note from Zacks regarding the stock slipping below its 50-day moving average and downward EPS estimate revisions. Investors are encouraged to watch upcoming macro-economic data, healthcare policy narratives, technical levels, and dividend schedules as the market approaches the next regular session on Monday, December 15, 2025.

**3. Canada Pension Plan Investment Board Has $466.58 Million Stake in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251212T140731 | Bullish | Relevance: 100%
- The Canada Pension Plan Investment Board significantly increased its stake in AbbVie Inc. by 43.3% to 2,513,624 shares, valuing its holding at approximately $466.58 million. AbbVie reported strong Q2 earnings, exceeding revenue and EPS estimates, and raised its quarterly dividend to $1.73 per share, representing an annualized yield of 3.1%. Analysts maintain a "Moderate Buy" rating with a consensus price target of $243.85.

**4. AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock**
- Source: Finviz | 20251212T140048 | Somewhat-Bullish | Relevance: 100%
- AbbVie's stock (ABBV) recently fell below its 50-day simple moving average, indicating short-term selling pressure despite a strong long-term trend above its 200-day SMA. This article analyzes AbbVie's strengths, such as the success of new drugs Skyrizi and Rinvoq and its robust pipelines in oncology and neuroscience, against weaknesses like Humira's patent expiration and struggling aesthetics sales. The author concludes that investors should remain invested, citing AbbVie's robust pipeline, strong revenue growth expectations for 2025, and reasonable valuation.

**5. Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth**
- Source: The Globe and Mail | 20251211T140757 | Somewhat-Bullish | Relevance: 100%
- AbbVie's oncology segment now accounts for over 11% of its total revenues, driven by both organic pipeline development and strategic acquisitions. While new drugs like Epkinly, Elahere, and Emrelis, alongside Venclexta, are boosting sales, the company is also expanding its portfolio with antibody-drug conjugates (ADCs) and other innovative therapies. Despite competition from major players like AstraZeneca, Merck, and Pfizer, AbbVie shows strong performance and a robust pipeline in the oncology space.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.40 indicates undervaluation relative to growth. Forward P/E 15.7x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.7B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.40 |
| Forward P/E | 15.7 |
| Current P/E | 21.0 |
| YoY Growth | 34.0% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -4.6% to -2.7% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.75), momentum weakening. RSI neutral at 45. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.66% (CS: 17) | Weak |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $223.32
- **Stop Loss:** $213.58 (4.4% risk)
- **Target:** $242.80 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $22,778.64
- **Portfolio %:** 22.78%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*